Overview

* LifeStance Health Group ( LFST ) Q2 revenue rises 11% to $345.3 mln, beating analyst expectations

* Net loss of $3.8 mln beats analyst estimates

* Adjusted EBITDA increases 19% to $34 mln, exceeding analyst estimates

Outlook

* Company reiterates full-year revenue of $1.40 bln to $1.44 bln

* Lifestance raises full-year Adjusted EBITDA to $140 mln to $150 mln

* Company expects Q3 revenue of $345 mln to $365 mln

* Lifestance sees Q3 Adjusted EBITDA of $33 mln to $39 mln

Result Drivers

* CLINICIAN GROWTH - Revenue growth driven by 11% increase in clinician base, resulting in higher visit volumes

* OPERATING LEVERAGE - Adjusted EBITDA rose due to revenue growing faster than general and administrative expenses

* FREE CASH FLOW - Strong free cash flow of $57 mln attributed to improved operational performance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $345.30 $345.20

Revenue mln mln (8

Analysts

)

Q2 Net Beat -$3.80 -$9.87

Income mln mln (6

Analysts

)

Q2 Beat $34 mln $31.10

Adjusted mln (7

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for LifeStance Health Group Inc ( LFST ) is $8.25, about 52.7% above its August 6 closing price of $3.90

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)